Study Design
DesignRandomized, double-blind, dose-ranging
BlindingDouble-blind
Enrollment313
Treatment Arms
Sonelokimab 120mg augmented 120mg SC augmented loading n=51
Sonelokimab 60mg 60mg SC n=52
Secukinumab 300mg (reference) 300mg SC n=52
Placebo Matching placebo n=52
[{"id":"pasi90-w12","name":"PASI 90 at Week 12","type":"PRIMARY","unit":"%","results":[{"value":76.5,"arm_id":"son120-arm","p_value":0.001},{"value":77,"arm_id":"son60-arm"},{"value":73.6,"arm_id":"sec-arm"},{"value":0,"arm_id":"pbo-arm"}],"timepoint":"Week 12"}]
Phase 2b data was competitive (~77% PASI 90 Wk12) but no Phase 3 in PsO planned. Moonlake pivoted to HS (VELA) and PsA (IZAR). No H2H vs bimekizumab exists. Cross-trial comparison unreliable. Smaller nanobody format (~40 kDa vs 150 kDa) may have PK disadvantages (shorter half-life, monovalent binding). VELA HS Phase 3 results mixed.